Startup Pitches ‘Brainless Clones’ To Serve the Role of Backup Human Bodies

MIT Technology Review discovered that startup R3 Bio has pitched an ethically and scientifically explosive long-term vision beyond its public work on non-sentient monkey “organ sacks”: creating human “brainless clones” or replacement bodies for organs as part of an extreme life-extension agenda. From the report: Imagine it like this: a baby version of yourself with only enough of a brain structure to be alive in case you ever need a new kidney or liver. Or, alternatively, he has speculated, you might one day get your brain placed into a younger clone. That could be a way to gain a second lifespan through a still hypothetical procedure known as a body transplant.

The fuller context of R3’s proposals, as well as activities of another stealth startup with related goals, have not previously been reported. They’ve been kept secret by a circle of extreme life-extension proponents who fear that their plans for immortality could be derailed by clickbait headlines and public backlash. And that’s because the idea can sound like something straight from a creepy science fiction film. One person who heard R3’s clone presentation, and spoke on the condition of anonymity, was left reeling by its implications and shaken by [R3 founder John Schloendorn’s] enthusiastic delivery. The briefing, this person said, was like a “close encounter of the third kind” with “Dr. Strangelove.” […]

MIT Technology Review found no evidence that R3 has cloned anyone, or even any animal bigger than a rodent. What we did find were documents, additional meeting agendas, and other sources outlining a technical road map for what R3 called “body replacement cloning” in a 2023 letter to supporters. That road map involved improvements to the cloning process and genetic wiring diagrams for how to create animals without complete brains. A main purpose of the fundraising, investors say, was to support efforts to try these techniques in monkeys from a base in the Caribbean. That offered a path to a nearer-term business plan for more ethical medical experiments and toxicology testing — if the company could develop what it now calls monkey “organ sacks.” However, this work would clearly inform any possible human version.